Table 3.

Comparison of post hoc exploratory secondary outcomes between the haloperidol and placebo group

Outcome	Haloperidol (n = 65)	Placebo (n = 67)	Adjusted relative risk (95% CI)a	p value
No. of days with study drug, median (IQR)	4 (3–8)	6 (3–9)	0.96 (0.79–1.16)	0.66
No. of delirium days, median (IQR)	3 (2–6.5)	3 (2–5)	1.05 (0.81–1.37)	0.722
No. of coma days, median (IQR)	0 (0–2)	0 (0–1)	1.5 (0.85–2.66)	0.164
Agitation (RASS > 1), n (%)	25 (39)	30 (45)	OR: 0.84 (0.4–1.75)	0.638
No. of days, median (IQR)	0 (0–1)	0 (0–1)	0.77 (0.43–1.39)	0.388
Hallucinations/delusions, n (%)	55 (85)	51 (76)	OR: 1.75 (0.72–4.4)	0.220
No. of days, median (IQR)	2 (1–3)	3 (1–4.5)	0.74 (0.53–1.03)	0.075
Removal of urinary catheter, n (%)	5 (8)	9 (13)	OR: 0.48 (0.14–1.52)	0.226
Physical restraint, n (%)	48 (74)	48 (72)	OR: 1.19 (0.54–2.64)	0.660
(Almost) fell or stepped out of bed, n (%)	6 (9)	18 (27)	OR: 0.32 (0.11–0.84)	0.026

CI confidence interval, IQR interquartile range, NA not applicable, OR odds ratio, RR relative risk

^aRR unless otherwise noted. The placebo group is used as reference